| Vesigen Therapeutics–Bayer: investment, 202007 financing round Series A totalling $28.5m incl co-lead investor Leaps by Bayer |
2020-07-22 |
| Vesigen Therapeutics–SEVERAL: investment, 202007 financing round Series A $28.5m co-led by Leaps by Bayer + Morningside Ventures |
2020-07-22 |
| Gain Therapeutics–SEVERAL: investment, 202007 financing round Series B $10m from institutional + accredited investors |
2020-07-21 |
| Quantro Therapeutics–Boehringer: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes |
2020-07-21 |
| Quantro Therapeutics–Evotec: drug discovery services, 202007– supply of hit identification services by Evotec |
2020-07-21 |
| Quantro Therapeutics–Evotec: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes |
2020-07-21 |
| Quantro Therapeutics–MC Services: public relations, 202007 service existent by MC Services |
2020-07-21 |
| Quantro Therapeutics–SEVERAL: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes |
2020-07-21 |
| Tubulis–Bavaria (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Bayern Kapital |
2020-07-21 |
| Tubulis–BioMedPartners: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor BioMedPartners |
2020-07-21 |
| Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners |
2020-07-21 |
| Tubulis–Germany (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Coparion |
2020-07-21 |
| Tubulis–High-Tech Gründerfonds: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor HTGF |
2020-07-21 |
| Tubulis–Occident Group: investment, 202007 financing round Series A totalling €10.7m incl co-investor Occident Group |
2020-07-21 |
| Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF |
2020-07-21 |
| Tubulis–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-21 |
| CureVac–Germany (govt): investment, 202007 financing round Series B totalling €560m incl €300m from KfW approx 19% shareholding |
2020-07-17 |
| CureVac–GSK: investment, 202007 financing round Series B totalling €560m incl €150m from Glaxo Group Ltd |
2020-07-17 |
| CureVac–Qatar (govt): investment, 202007 financing round Series B totalling €560m incl €60m from Qatar Investment Authority |
2020-07-17 |
| CureVac–SEVERAL: investment, 202007 financing round Series B €560m incl €300m from KfW + €150m from GSK + €60m from QIA |
2020-07-17 |
| TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group |
2020-07-16 |
| Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina |
2020-07-14 |
| Anergis–Virometix: allergy immunotherapy, 202007– collab research study at HZI using SVLPs supported by TRANSVAC2 grant in house dust mite allergy |
2020-07-09 |
| CirQuest Labs–MLM Medical Labs: investment, 202007 acquisition of CirQuest Labs by MLM Medical Labs |
2020-07-08 |
| Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-08 |
| Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties |
2020-07-08 |
| Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund |
2020-07-03 |
| Bright Peak Therapeutics–SEVERAL: investment, 202007 financing round Series A $35m |
2020-07-01 |
| Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck |
2020-07-01 |
| Roche–Inveox: sample management software, 202007– collab digitization Vantage Workflow Solution for histopathology labs with Roche Diagnostics |
2020-07-01 |
| Waters–Heidrick & Struggles: recruitment services, 202007 supply service placement of Udit Batra as CEO of Waters |
2020-07-01 |
| DeepSpin–Apex Ventures: investment, 202006 seed financing round totalling €600k incl new + lead investor Apex Digital Health |
2020-06-30 |
| DeepSpin–Entrepreneur First: investment, 202006 seed financing round totalling €600k incl existing + co-investor EF |
2020-06-30 |
| DeepSpin–OTHER: investment, 202006 seed financing round totalling €600k incl several business angels |
2020-06-30 |
| DeepSpin–SEVERAL: investment, 202006 seed financing round €600k from Apex Digital Health + EF + SOSV + business angels |
2020-06-30 |
| DeepSpin–SOSV: investment, 202006 seed financing round totalling €600k incl existing + co-investor SOSV |
2020-06-30 |
| CRISPR Therapeutics–SEVERAL: investment, 202006– public offering $450m+67.5m with 6.43m+964.3k common shares at $70/share |
2020-06-29 |
| Cutiss–Gisev Family Office: investment, 202006 financing round Series B totalling CHF20m incl lead investor Gisev Familiy Office |
2020-06-29 |
| Cutiss–SEVERAL: investment, 202006 financing round Series B CHF20m led by Gisev Familiy Office |
2020-06-29 |
| ArcherDx–Invitae: investment, 202006– acquisition merger up to $1.4b with $325m cash + 30m shares + up to addit 27m shares milestone-dependent |
2020-06-22 |
| RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion |
2020-06-22 |
| Kaia Health–SEVERAL: investment, 202006 financing round Series B $26m led by Optum Ventures + Idinvest + capital300 |
2020-06-18 |
| Univ Bochum–Max Planck: antibiotics research, 202006– collab establishment CESAR Center for Antibiotics Research at Univ Bochum with LDC |
2020-06-18 |
| Univ Bochum–North Rhine-Westphalia (govt): grant, 202006– grant €4m from NRW + EFRO for establishment CESAR Center for Antibiotics Research with LDC |
2020-06-18 |
| C4 Therapeutics–SEVERAL: investment, 202006 financing round Series B $150m co-led by Cobro Ventures + Perceptive Advisors |
2020-06-16 |
| DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF |
2020-06-16 |
| DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund |
2020-06-16 |
| eTheRNA–Boehringer: investment, 202006 financing round Series B totalling €34m incl existing investor BIVF |
2020-06-16 |
| eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors |
2020-06-16 |
| Qurient–Max Planck: proteasome inhibitors, 2012006– collab develop + license + founding of joint venture QLi5 Therapeutics GmbH |
2020-06-16 |
| Bit Bio–BY Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor BlueYard Capital |
2020-06-13 |
| Bit Bio–Mission Group: public relations, 202006 service existent by April Six |
2020-06-13 |
| Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum |
2020-06-13 |
| Lexent Bio–Roche: investment, 202006 acquisition of Lexent Bio by Foundation Medicine |
2020-06-12 |
| 10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM |
2020-06-10 |
| Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF |
2020-06-10 |
| Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV |
2020-06-10 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation |
2020-06-10 |
| Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Royalty Pharma–AiCuris: letermovir, 202006 acquisition of partial royalty interest on letermovir for one-time payment of $220m by Royalty Pharma |
2020-06-09 |
| Everest Medicines–SEVERAL: investment, 202006 financing round Series C $310m led by Janchor Partners + co-led by RA CApital + Hillhouse Capital |
2020-06-04 |
| BRAIN–SEVERAL: investment, 202006 private placenment €14.94m with 1.8m new shares at €8.3/share |
2020-06-03 |
| AdvanceCor–Bavaria (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor Bayern Kapital |
2020-06-02 |
| AdvanceCor–First Capital Partner: investment, 202006 financing round totalling €3.9m incl co-investor First Capital Partner |
2020-06-02 |
| AdvanceCor–Germany (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor KfW Bank |
2020-06-02 |
| AdvanceCor–MIG Fonds: investment, 202006 financing round totalling €3.9m incl existing + lead investor MIG AG |
2020-06-02 |
| AdvanceCor–Occident Group: investment, 202006 financing round totalling €3.9m incl existing + co-investor Occident |
2020-06-02 |
| AdvanceCor–SEVERAL: investment, 202006 financing round €3.9m led by MIG AG |
2020-06-02 |
| Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility |
2020-05-27 |
| KI-SIGS project–Germany (govt): grant, 202005– funding €10m from German federal government |
2020-05-27 |
| Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital |
2020-05-27 |
| Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF |
2020-05-27 |
| Kumovis–Renolit: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Renolit SE |
2020-05-27 |
| Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures |
2020-05-27 |
| Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures |
2020-05-27 |
| Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital |
2020-05-26 |
| Monte Rosa Therapeutics–New Enterprise Associates: investment, 202005 discloses financing round Series A totalling $32.5m incl investor NEA |
2020-05-26 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202005 emerges from stealth + discloses financing round Series A $32.5m from Versant + NEA |
2020-05-26 |
| Monte Rosa Therapeutics–Versant Ventures: investment, 202005 discloses financing round Series A totalling $32.5m incl founding investor Versant |
2020-05-26 |
| Spindiag–Baden-Württemberg (govt): grant, 202004 grant €6m for Spindiag + HSI-IMIT from Ministry of Economic Affairs |
2020-05-26 |
| Spindiag–SEVERAL: investment, 202005 financing round Series B €16.3m with investors WBG Pflegeheime + Think-Health Ventures et al. |
2020-05-26 |
| Spindiag–Think.Health Ventures: investment, 202005 financing round Series B totalling €16.3m incl new investor Think.Health Ventures |
2020-05-26 |
| Spindiag–WBG Pflegeheime: investment, 202005 financing round Series B totalling €16.3m incl existing investor WBG Pflegeheime |
2020-05-26 |
| Sterna Biologicals–MC Services: public relations, 202005 service existent by MC Services |
2020-05-26 |
| Sterna Biologicals–SEVERAL: investment, 202005 financing round Series A first closing €12m with existing + new investors |
2020-05-26 |
| Themis Bioscience–Merck (US): investment, 202005– acquisition €na all remaing shares of Themis via Merck subsidiary |
2020-05-26 |
| Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications |
2020-05-25 |
| Stratos–Roche: investment, 202005 acquisition €na of Stratos Genomics by Roche |
2020-05-22 |
| Idorsia–SEVERAL: investment, 202005 capital increase CHF330m offering of 11m new shares at CHF30/share to qualified investors |
2020-05-19 |
| Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins |
2020-05-19 |
| Rentschler–MC Services: public relations, 202005 service existent by MC Services |
2020-05-19 |
| Apeiron–Austria (govt): grant, 202005– grant funding + guarantees €5.6m from FFG + WAW + AWS + Erste Bank |
2020-05-18 |
| Apeiron–SEVERAL: investment, 202005–202006 private placement €11.9m led by Vienna Insurance Group plus existing + new investors |
2020-05-18 |
| Apeiron–Vienna Insurance Group: investment, 202005–202006 private placement totalling €11.9m incl €7m from new + lead investor VIG |
2020-05-18 |
| Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon |
2020-05-16 |
| OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader |
2020-05-16 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 4 5 ... 30 31 32 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
